Eagle Pharmaceuticals Inc (EGRX)
3.47
+0.04
(+1.31%)
USD |
NASDAQ |
May 31, 16:00
3.45
-0.02
(-0.58%)
After-Hours: 20:00
Eagle Pharmaceuticals Research and Development Expense (Quarterly): 9.833M for June 30, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2023 | 9.833M |
| March 31, 2023 | 9.272M |
| December 31, 2022 | 7.217M |
| September 30, 2022 | 9.326M |
| June 30, 2022 | 11.44M |
| March 31, 2022 | 6.108M |
| December 31, 2021 | 3.787M |
| September 30, 2021 | 23.29M |
| June 30, 2021 | 9.911M |
| March 31, 2021 | 14.29M |
| December 31, 2020 | 9.395M |
| September 30, 2020 | 4.828M |
| June 30, 2020 | 7.135M |
| March 31, 2020 | 9.427M |
| December 31, 2019 | 11.31M |
| September 30, 2019 | 10.17M |
| June 30, 2019 | 8.957M |
| March 31, 2019 | 6.375M |
| December 31, 2018 | 5.859M |
| September 30, 2018 | 5.975M |
| June 30, 2018 | 15.26M |
| March 31, 2018 | 17.32M |
| Date | Value |
|---|---|
| December 31, 2017 | 9.444M |
| September 30, 2017 | 8.954M |
| June 30, 2017 | 6.684M |
| March 31, 2017 | 7.525M |
| December 31, 2016 | 14.68M |
| September 30, 2016 | 3.207M |
| June 30, 2016 | 3.799M |
| March 31, 2016 | 5.521M |
| December 31, 2015 | 8.782M |
| September 30, 2015 | 6.911M |
| June 30, 2015 | 5.878M |
| March 31, 2015 | 6.285M |
| December 31, 2014 | 3.986M |
| September 30, 2014 | 5.888M |
| June 30, 2014 | 4.545M |
| March 31, 2014 | 3.794M |
| December 31, 2013 | 2.589M |
| September 30, 2013 | 3.419M |
| June 30, 2013 | 1.632M |
| March 31, 2013 | 2.525M |
| December 31, 2012 | 2.219M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
3.787M
Minimum
Dec 2021
23.29M
Maximum
Sep 2021
9.746M
Average
9.395M
Median
Dec 2020
Research and Development Expense (Quarterly) Benchmarks
| Baxter International Inc | 176.00M |
| Soligenix Inc | 1.095M |
| Marinus Pharmaceuticals Inc | 24.12M |
| BioXcel Therapeutics Inc | 11.40M |
| NovaBay Pharmaceuticals Inc | 0.019M |